Stock Analysis on Net
Stock Analysis on Net

Pfizer Inc. (NYSE:PFE)

Common-Size Income Statement
Quarterly Data

Pfizer Inc., common-size consolidated income statement (quarterly data)

Microsoft Excel
3 months ended: Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022 Dec 31, 2021 Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020 Dec 31, 2019 Sep 29, 2019 Jun 30, 2019 Mar 31, 2019
Revenues 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost of sales -53.07 -70.05 -25.42 -26.73 -39.73 -26.78 -31.17 -38.91 -40.84 -41.32 -37.02 -28.64 -24.98 -19.53 -18.51 -19.24 -20.55 -20.52 -19.42 -18.55
Gross profit 46.93% 29.95% 74.58% 73.27% 60.27% 73.22% 68.83% 61.09% 59.16% 58.68% 62.98% 71.36% 75.02% 80.47% 81.49% 80.76% 79.45% 79.48% 80.58% 81.45%
Selling, informational and administrative expenses -32.11 -24.80 -27.46 -18.70 -19.12 -14.98 -10.99 -10.10 -17.22 -12.06 -15.47 -19.13 -32.16 -25.86 -26.96 -25.20 -33.42 -25.71 -26.47 -25.45
Research and development expenses -19.76 -20.49 -20.79 -13.70 -14.89 -11.91 -10.15 -8.97 -14.46 -11.15 -11.85 -13.74 -28.71 -22.38 -21.07 -16.58 -22.24 -18.00 -13.89 -12.98
Acquired in-process research and development expenses -0.51 -0.51 -0.26 -0.11 -0.30 -2.31 0.00 -1.38 -10.36 -3.17 -1.16 -0.13 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Amortization of intangible assets -8.89 -8.91 -9.30 -6.03 -4.65 -3.63 -2.96 -3.25 -4.01 -4.03 -4.85 -5.91 -7.33 -8.39 -8.81 -8.42 -8.13 -9.56 -8.93 -9.02
Restructuring charges and certain acquisition-related costs -18.00 -1.17 -1.68 -0.05 -3.27 -0.88 -0.68 -0.75 -0.57 -2.69 0.01 -0.15 -1.57 -0.02 -3.65 -0.54 -3.55 -2.88 0.87 -0.35
Operating income (loss) -32.35% -25.92% 15.09% 34.68% 18.04% 39.50% 44.05% 36.64% 12.55% 25.58% 29.66% 32.30% 5.25% 23.82% 21.01% 30.02% 12.11% 23.33% 32.16% 33.65%
Gain on completion of Consumer Healthcare JV transaction 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.06 -0.01 63.78 0.00 0.00
Other income (deductions), net 3.37 0.59 2.73 -0.38 3.50 0.26 -2.78 -1.36 3.51 7.06 7.10 6.92 3.82 -18.27 9.67 -1.89 -23.98 -2.51 -0.94 -0.70
Income (loss) from continuing operations before (provision) benefit for taxes on income (loss) -28.98% -25.33% 17.82% 34.30% 21.53% 39.76% 41.26% 35.27% 16.05% 32.63% 36.76% 39.22% 9.06% 5.55% 30.68% 28.19% -11.89% 84.60% 31.22% 32.95%
(Provision) benefit for taxes on income (loss) 5.57 7.29 0.56 -3.91 -0.95 -1.57 -5.66 -4.57 -1.04 1.36 -5.94 -5.57 -0.36 3.38 -4.28 -3.56 9.31 -24.03 6.90 -3.30
Income (loss) from continuing operations -23.41% -18.05% 18.38% 30.39% 20.59% 38.19% 35.60% 30.70% 15.01% 34.00% 30.82% 33.65% 8.70% 8.92% 26.40% 24.63% -2.58% 60.57% 38.12% 29.65%
Discontinued operations, net of tax -0.18 0.09 -0.02 0.01 0.01 -0.10 0.12 -0.04 -0.78 -0.05 -1.25 0.01 2.54 5.45 9.05 8.74 0.00 0.03 0.00 0.00
Net income (loss) before allocation to noncontrolling interests -23.58% -17.96% 18.36% 30.39% 20.60% 38.09% 35.73% 30.67% 14.23% 33.95% 29.57% 33.66% 11.25% 14.37% 35.45% 33.36% -2.58% 60.60% 38.12% 29.65%
Net income attributable to noncontrolling interests -0.06 -0.05 -0.09 -0.07 -0.04 -0.07 -0.02 -0.02 0.01 -0.05 -0.14 -0.06 -0.09 -0.08 -0.08 -0.09 -0.08 -0.03 -0.08 -0.04
Net income (loss) attributable to Pfizer Inc. -23.65% -18.00% 18.27% 30.32% 20.56% 38.02% 35.71% 30.65% 14.23% 33.89% 29.44% 33.60% 11.15% 14.29% 35.37% 33.27% -2.66% 60.57% 38.04% 29.61%
Preferred stock dividends, net of tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 -0.01 -0.01
Net income (loss) attributable to Pfizer Inc. common shareholders -23.65% -18.00% 18.27% 30.32% 20.56% 38.02% 35.71% 30.65% 14.23% 33.89% 29.44% 33.60% 11.15% 14.29% 35.37% 33.27% -2.65% 60.57% 38.04% 29.60%

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

Income statement item Description The company
Operating income (loss) The net result for the period of deducting operating expenses from operating revenues. Pfizer Inc. operating income (loss) as a percentage of revenues decreased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.
Income (loss) from continuing operations before (provision) benefit for taxes on income (loss) Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Pfizer Inc. income (loss) from continuing operations before (provision) benefit for taxes on income (loss) as a percentage of revenues decreased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.
Net income (loss) attributable to Pfizer Inc. The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Pfizer Inc. net income (loss) attributable to Pfizer Inc. as a percentage of revenues decreased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.